I'm a neuroscientist. I scanned my own brain 26 times to see how it changed during pregnancy.
I'm a researcher who specializes in learning and memory, and I use magnetic resonance imaging (MRI) regularly in my work. But the tables turned, and I ended up becoming the subject of a study of the human brain during pregnancy when I was trying to conceive.
I was inspired by Laura Pritschet, a graduate student working at the University of California, Santa Barbara, under my colleague, Emily Jacobs. Pritschet had recently finished a study on herself on how the menstrual cycle impacts the brain, and it made me think I should do the same during my pregnancy journey in 2019.
I went through in vitro fertilization, so I had a great idea of the timing of my pregnancy. All that was left to do was to track myself, and I did — over 26 MRI scans.
I'm used to doing MRIs quite a bit, given my field. I know that the American College of Obstetricians and Gynecologists says that MRIs are not linked with pregnancy risk and are the imaging techniques of choice when they're needed during pregnancy.
MRI uses a magnet, and there are no injections or radiation. There are no known risks, but we looked at studies of people who had done MRIs during pregnancy for medical reasons, and there were no safety concerns. I did want to be cautious about sound, so we put some foam in the machine as an added precaution to muffle the sound the scanner makes.
After that, I worked with my collaborators to come up with the protocols that would be needed for the scans. It ended up being that I simply made appointments to be in the MRI scanner and to do blood draws as well. I tried to time the blood draws to happen just before the scans so the data would be gathered as close together as possible.
The MRI sessions weren't short. We did about six or seven different scans each time, ultimately taking about 40 minutes each. I did 26 scans overall, which means I spent more than 1,000 minutes in an MRI scanner before, during and after my pregnancy.
During each scan, I had to get set up, be positioned well and just try to get comfortable. Later on in my pregnancy, it was more important just to be comfortable.
I had to lay still and stay awake for one of the scans, so I would just think about whatever I wanted during that time. We made a point to do that scan first, and it usually was over in 10 minutes. After that, I would just rest or fall asleep during the other scans. I usually slept — I was pregnant, after all.
The research on my brain was eventually published in the journal Nature Neuroscience, featuring photos and breakdowns of all of my scans. We saw some noticeable changes to my brain over time.
One big standout was in the volume of gray matter in my brain. Gray matter is a type of tissue that's mostly responsible for processing memory, along with sensory perception, speech and decision-making. The gray matter decreased about 4%, and those changes are pretty permanent. In tracking this, we could see a steady decrease and a slight bounce back in volume, but it never really fully returned. I haven't noticed a change in how I think, though.
We also looked at white matter, which acts as the 'superhighway' in the brain to form big connections. We think of this as the road information travels on. Here, we found an interesting change where the structural integrity of white matter improved and peaked around the second trimester before returning to baseline after my baby was born. Again, I didn't notice a difference in how I thought or felt during this time.
The purpose of the study was to look for changes in the brain during pregnancy. It's 2025, and it's shocking how little we know about some of these things. There were basically no studies on brain changes during pregnancy, so it was up to us to do the research. But we don't know yet what these findings mean.
We don't know if these brain changes are good or not. There is some suggestion that these changes are adaptive, morphing the brain on purpose to help with maternal care. But it could also be a trade-off. The body may be saying, 'We've got other things to do here. Sorry, brain!' and shuttling vital resources away from the brain to other areas. So, we really don't know. Now, we need to find out what all of this means.
General interest in this area of research has opened up, and there's been a very big response in the research community to our work. We're now working with other people and plan to do another round with a bigger sample of 10 to 15 pregnant women. After that, we'll scan hundreds of pregnant women but with fewer time points.
I'm lucky that I had no major issues with postpartum depression, but estimates from the Centers for Disease Control and Prevention show that up to one in eight women do. We're keeping an eye toward postpartum depression with our research and who is most vulnerable. The hope is that we can help to identify how the risks of postpartum depression change during pregnancy along with where, when and how we can help to prevent it.
Ultimately, the big thing is that we actually did the study and asked the questions. This is a huge area of research that has been overlooked — and we're actively trying to change that.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
37 minutes ago
- Associated Press
Nanobles Corporation Contracts Akoode Tech to Build Plant Chat® Open AI Website
Nanobles announces contract on Plant Chat®, an AI-powered platform for plant enthusiasts, growers, gardeners, plant medicine users, consumers, and researchers 'We were founded in 2020, but we've expanded from IP and are now offering our holdings. Nanobles' new mission is also to help people Get Balanced by teaching how to support the body's Master Regulator.'— Mike Robinson, CEO, Nanobles, Inc. SANTA BARBARA, CA, UNITED STATES, August 15, 2025 / / -- Nanobles Corporation has officially partnered with Akoode Technologies, a leading global AI and software development firm, to develop the full-scale Plant Chat® platform and its new standalone website. Designed for all plant enthusiasts - from growers and gardeners to plant medicine users and researchers - Plant Chat® will serve as a research-grade, user-focused ecosystem for education, cultivation support, and scientific discovery. 'This is something we've been working on behind the scenes for years as part of the bigger picture for Nanobles Corporation. As an IP holding corporation, there comes a time when you have to release certain assets into the world and step into new arenas,' explained Nanobles CEO Mike Robinson. 'AI's momentum started building several years ago, and my partner was ahead of the curve in bringing this idea forward. Plant Chat is the result of that foresight - a platform built to merge plant-based science with advanced technology in a way that makes a real difference.' As part of its broader growth strategy, Nanobles also announced it is moving to conclude its merger with the Global Cannabinoid Research Center (GCRC). This transition will allow Nanobles to sharpen its focus on Nutraceutical innovation with its two star brands, Get Balanced® and Nano Terps®, the launch and expansion of Plant Chat® AI, the Get Balanced® Research Initiative on the ECS, and the licensing of its vast intellectual property portfolio. 'Back in mid-2024, Nanobles and the Global Cannabinoid Research Center merged to combine GCRC's science and IP with Nanobles' corporate structure and brand-building capabilities. At the time, it made sense to operate under one roof, especially as we built out our trademark and licensing division, " Stated Nanoble's David Uhalley. 'But as of 2025, it's clear our focus has shifted. The paperwork is complete, Robinson has regained GCRC, minus a significant amount of IP he contributed to Nanobles, which now anchors our licensing and brand portfolio.' David Uhalley, the corporation's IP officer, explains, 'We're fully non-cannabis, working with nutraceuticals, botanical terpenes, and other plant-based innovations. With Plant Chat® ready to launch, the split allows us to stay mission-focused and build without the distraction of the endlessly changing industry that surrounds the GCRC name. I'm excited about how my ECS responds to nutraceutical therapies, and with Plant Chat coming in the 3rd quarter, we're all eager to see it live. Plant Chat® will deliver a unique experience where users can create their own verified user account, and: ** Log plant growth and care – track watering schedules, nutrient inputs, pruning dates, and other cultivation activities. ** Record plant medicine use – document doses, blends, and effects while monitoring wellness outcomes. ** Participate in research surveys – contribute to structured, privacy-controlled studies that advance global plant science. ** Get AI-powered insights – receive personalized feedback based on logs, plant data, and user goals. ** Access tailored education – explore articles on the Plant Chat® Blog ** Use Plant Chat® - An AI-powered engine, far more than a search, for plant science, education, and interactive research . Akoode Technologies will design a responsive, secure, and scalable platform that integrates user verification, interactive logging, and real-time survey capabilities. The new website will be fully SEO-optimized, visually dynamic, and purpose-built to give Plant Chat® its own independent identity outside of Nanobles' corporate site. 'Plant Chat® is not just another wellness app – it's a living research hub where people, plants, and science meet,' said Mike Robinson, CEO of Nanobles Corporation. 'We're giving everyday users the tools to understand plants and their health better while producing valuable, research-grade data that benefits the global plant medicine community.' 'Ending the GCRC merger is simply about focus. Nanobles is committed to scaling Plant Chat®, expanding our nutraceuticals, and advancing ECS research while strategically licensing our IP to partners who share our mission. We're excited about working with Akoode. They've shown their immense worth to our team to date, and I know they'll continue to do so under their very professional leadership, " Robinson explained. 'Partnering with Nanobles on Plant Chat® and the new corporate site is more than just a project – it's a vision for the future,' said Akhil Verma, CEO of Akoode Technologies. 'At Akoode, we believe in building technologies that not only perform but transform, and this collaboration is a perfect example. Working with a pioneer like Mike Robinson and the Nanobles team, we're not just delivering code – we're shaping a future where artificial intelligence and plant-based science come together to change lives.' 'From personalized education to real-time phyto-intelligence, Plant Chat will guide users through logs, journeys, learning paths, surveys, and even personalized wellness ecosystems that Nanobles will offer. Future versions of the platform will go beyond the Beta launch that's coming soon. Plant Chat® is the kind of work that drives our team: mission-aligned, globally scalable, and built for impact,' stated Verma. The Plant Chat® platform will integrate features such as verified user accounts, customizable logs and settings, and data-sharing controls for premium users in its future versions, offering enhanced options for controlling their research participation. By combining these tools with educational resources and interactive tracking, Plant Chat® will provide both practical daily use and significant value for global research initiatives. The platform and new website are both scheduled to beta launch in less than 2 months, the third quarter of 2025, marking a significant step forward in Nanobles' expansion into interactive, technology-driven plant medicine solutions. 'We'll be working towards a hard launch with the full Open AI driven website in the 4th quarter, due to the cost just to run the platform we're looking for investment partners to bring us to the next level, but we're starting the Get Balanced® Research Initiative with the beta launch that's coming in Q3 to show what we're able to do to those that can finance many new versions - we've even spoken of white label to universities and more,' Nanobles CEO Mike Robinson explains. 'But more than anything, we look forward to consumers signing up to use it, for people to have it on the phone, tablet, or desktop.' In its beta launch, Plant Chat® will offer an open and accessible user experience - anyone can sign up for free. As users join and verify their accounts, the first wave of survey studies will begin, allowing participants to contribute to early-stage research. During this period, the platform will operate through Plant Chat® on GPT, giving users immediate access to its AI-driven features ahead of the upcoming hard launch, which will introduce the full suite of tools and capabilities. 'Even after we're offering premium accounts, we'll also have a freemium platform that everyone can use and have their interactive profiles. " David Uhalley continued, 'We're looking to offer the world something that it's never seen before, and allow users who sign up initially to keep their accounts - along with anyone else who doesn't have the funds for Premium.' The global AI market is experiencing rapid expansion, with valuations projected to surpass $1 trillion in the coming decade as industries integrate artificial intelligence into everyday processes. OpenAI-driven platforms are at the forefront of this shift, delivering personalized, adaptive, and data-rich user experiences. Plant Chat® represents Nanobles' entry into this transformative space, a unique blend of plant science, wellness tracking, and research participation. By combining the depth of botanical knowledge with the adaptability of AI, Plant Chat® positions Nanobles Corporation not just as a nutraceutical innovator but as a technology company shaping how people interact with plants and their health. About Nanobles Corporation Founded in 2020 as an intellectual property (IP) holding corporation, Nanobles is now moving forward with a portfolio of offerings in nutraceuticals, botanical terpene formulations, AI-driven platforms, and brand licensing. The company develops plant-based wellness solutions and technologies that support the body's Master Regulator – the Endocannabinoid System (ECS) – while creating scalable IP for licensing to mission-aligned partners. Through its research initiatives and product innovations, Nanobles bridges natural science and advanced technology to improve global wellness. About Akoode Technologies Akoode Technologies is a top-tier AI and software development company with offices in India and the USA, specializing in AI, deep learning, data science, and computer vision. Known for delivering cutting-edge digital solutions, Akoode helps businesses harness the power of intelligent automation, predictive analytics, and visual recognition systems. Their team builds custom mobile and web apps, AI-powered platforms, and enterprise solutions across industries like healthcare, fintech, logistics, and retail. With a strong global presence and a focus on innovation, Akoode is driving the future of technology with innovative, scalable, and reliable solutions. Mike Robinson NANOBLES, Inc. +1 805-617-9539 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Associated Press
an hour ago
- Associated Press
Backyard Season Is Great for Your Soul But Bad for Your Toenails? Crystal Flush Shares Why Long-Term Fungus Care Matters
08/14/2025, Los Angeles, CA // KISS PR Brand Story PressWire // Backyard BBQs are the highlight of summer—grilling, laughing, and kicking off your shoes to relax. But what if we told you that going barefoot or slipping into someone else's house sandals could secretly invite toe fungus? Fungus thrives in warm, damp places like patios, porches, or around kiddie pools. And when multiple people go shoeless or share slippers, the risk of fungal infection spread increases. Even if your feet appear clean, invisible spores can still enter through small cracks in the nail or skin. Here's the thing: toe fungus isn't just a surface problem. It often starts from within and that's why Crystal Flush Balance was created. This powerful supplement combines probiotics and plant-based ingredients to support your body's natural defense system from the inside. It's part of our 2-step system that treats the root of the problem and keeps flare-ups at bay—even after casual contact at social events. What most people don't know is that getting rid of toe fungus takes time—3 to 6 months, in fact—as the healthy nail slowly grows out. That's why we recommend following our 90-Day Protocol to see real results and maintain them long-term. Think of it like acne: it's not always a one-and-done fix, but ongoing care can make a huge difference. So next time you're heading to a backyard bash, enjoy yourself but protect your feet. Boost your body's defense with Crystal Flush Balance and stay one step ahead of fungus. Get it in as part of the Crystal Flush 2-step Antifungal System. Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice. Please consult your doctor for diagnosis and treatment options. Media Contact: Jason Gonor 888-717-5722
Yahoo
an hour ago
- Yahoo
Edwards Lifesciences Stock: Analyst Estimates & Ratings
With a market cap of $45.2 billion, Edwards Lifesciences Corporation (EW) is a global leader in innovative products and technologies for treating advanced cardiovascular diseases. The company specializes in transcatheter and surgical heart valve solutions, as well as critical care monitoring systems, serving patients across the United States, Europe, Japan, and worldwide. Shares of the Irvine, California-based company have underperformed the broader market over the past 52 weeks. EW stock has increased 17.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.7%. Moreover, shares of the company have risen 4.9% on a YTD basis, compared to SPX's 9.7% return. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, Edwards Lifesciences stock has outpaced the Health Care Select Sector SPDR Fund's (XLV) 12.1% decrease over the past 52 weeks. Shares of Edwards Lifesciences rose 5.5% following its Q2 2025 results on Jul. 24, with adjusted EPS of $0.67 and sales of $1.5 billion, both exceeding estimates and showing strong year-over-year growth. Segment strength was led by TAVR sales of $1.1 billion, TMTT sales of $134.5 million, and Surgical Structural Heart sales of $267 million. The company also raised its 2025 sales growth guidance to $5.90 billion - $6.10 billion and projected adjusted EPS at the high end of $2.40 - $2.50. For the fiscal year ending in December 2025, analysts expect EW's adjusted EPS to grow 2.9% year-over-year to $2.50. The company's earnings surprise history is promising. It topped or met the consensus estimates in the last four quarters. Among the 30 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 15 'Strong Buy' ratings, one 'Moderate Buy,' 13 'Holds,' and one 'Strong Sell.' This configuration is more bullish than three months ago, with 12 'Strong Buy' ratings on the stock. On Jul. 25, RBC Capital raised its price target on Edwards Lifesciences to $89 with an 'Outperform' rating. As of writing, the stock is trading below the mean price target of $87.28. The Street-high price target of $101 implies a modest potential upside of 30% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on